CCG-100602

SKU: orb1306106

Description

CCG-100602 is a cell-permeable inhibitor of RhoA/C-mediated SRF transcriptional activity, with an IC50 of 9.8 µM in PC-3 prostate cancer cells. This compound is a useful research tool for studying Rho GTPase signaling pathways in cancer cell biology and metastasis, both in vitro and in vivo.

Research Area

Cell Biology, Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 1207113-88-9
• MW: 478.82
• Purity: 99.86% (May vary between batches)
• Formula: C₂₁H₁₇ClF₆N₂O₂
• SMILES: FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CCCC(C1)C(=O)Nc1ccc(Cl)cc1
• Target: Ras,Rho
• Solubility: 10% DMSO+40% PEG300+5% Tween-80+45% Saline:1 mg/mL (2.09 mM);DMSO:100 mg/mL (208.85 mM)

Bioactivity

• In Vitro:
  CCG-100602 blocks the expression of MRTF-A/SRF-activated genes. CCG-100602 (3-30 μM) decreases the number of adherent hASC cells.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CCG100602, CCG-100602, CCG 100602, nuclear, localization, Inhibitor, myocardin, inhibit, MRTF-A, SRF, rho, serum, Ras, transcription

Compound Identifiers

PubChem CID

46190808